Mixing and matching N, N - and N, O -chelates in anionic Mg( i ) compounds: synthesis and reactivity with RN 00000000 00000000 00000000 00000000 11111111 00000000 11111111 00000000 00000000 00000000 C NR and CO †

Reduction of [Mg(NON)]2 ([NON]2− = [O(SiMe2NDipp)2]2−, Dipp = 2,6-iPr2C6H3) affords Mg(i) species containing NON- and NNO-ligands ([NNO]2− = [N(Dipp)SiMe2N(Dipp)SiMe2O]2−). The products of reactions with iPrNCNiPr and CO are consistent with the presence of reducing Mg(i) centres. Extraction with THF affords [K(THF)2]2[(NNO)Mg–Mg(NNO)] with a structurally characterised Mg–Mg bond that was examined using density functional theory

Reduction chemistry yields stable and soluble divalent lanthanide tris(pyrazolyl)borate complexes †

Reduction of the heteroleptic Ln(iii) precursors [Ln(Tp)2(OTf)] (Tp = hydrotris(1-pyrazolyl)borate; OTf = triflate) with either an aluminyl(i) anion or KC8 yielded the adduct-free homoleptic Ln(ii) complexes dimeric 1-Eu [{Eu(Tp)(μ-κ1:η5-Tp)}2] and monomeric 1-Yb [Yb(Tp)2]. Complexes 1-Ln have good solubility and stability in both non-coordinating and coordinating solvents. Reaction of 1-Ln with 2 Ph3PO yielded 1-Ln(OPPh3)2. All complexes are intensely coloured and 1-Eu is photoluminescent. The electronic absorption data show the 4f–5d electronic transitions in Ln(ii). Single-crystal X-ray diffraction data reveal first μ-κ1:η5-coordination mode of the unsubstituted Tp ligand to lanthanides in 1-Eu

Three oxidative addition routes of alkali metal aluminyls to dihydroaluminates and reactivity with CO2

Three distinct routes are reported to the soluble, dihydridoaluminate compounds, AM[Al(NONDipp)(H)2] (AM = Li, Na, K, Rb, Cs; [NONDipp]2– = [O(SiMe2NDipp)2]2–; Dipp = 2,6-iPr2C6H3) starting from the alkali metal aluminyls, AM[Al(NONDipp)]. Direct H2 hydrogenation of the heavier analogues (AM = Rb, Cs) produced the first examples of structurally characterized rubidium and caesium dihydridoaluminates, although harsh conditions were required for complete conversion. Using 1,4-cyclohexadiene (1,4-CHD) as an alternative hydrogen source in transfer hydrogenation reactions provided a lower energy pathway to the full series of products for AM = Li – Cs. A further moderation in conditions was noted for the thermal decomposition of the (silyl)(hydrido)aluminates, AM[Al(NONDipp)(H)(SiH2Ph)]. Probing the reaction of Cs[Al(NONDipp)] with 1,4-CHD provided access to a novel inverse sandwich complex, [{Cs(Et2O)}2{Al(NONDipp)(H)}2(C6H6)], containing the 1,4-dialuminated [C6H6]2– dianion and representing the first time that an intermediate in the commonly utilized oxidation process of 1,4-CHD to benzene has been trapped. The synthetic utility of the newly installed Al–H bonds has been demonstrated by their ability to reduce CO2 under mild conditions to form the bis-formate AM[Al(NONDipp)(O2CH)2] compounds, which exhibit a diverse series of eyecatching bimetallacyclic structures

Complexes of Iron(II) with silylated pentalene ligands; building blocks for homo- and heterobimetallics

A range of iron(II) complexes incorporating the silylated pentalene ligands (Pn†H = 1,4-{SiiPr3}2C8H5 and Pn† = 1,4-{SiiPr3}2C8H4) have been investigated as model molecules/building blocks for metallocene-based polymers. Six complexes have been synthesised and extensively characterised by a range of techniques, including by cyclic voltammetry and X-ray diffraction studies. Amongst these compounds are the homobimetallic [Cp∗Fe]2(μ-Pn†) which is a fused analogue of biferrocene, and the 3d/4s heterobimetallic [Cp∗Fe(η5-Pn†)][K] which forms an organometallic polymer in the solid state. DFT calculations on model mono-Fe(η5-Pn) compounds reveal the charge densities on the uncoordinated carbon atoms of the pentalene ligand, and hence the potential for incorporating these units into heteronuclear bimetallic complexes is assessed

Consensus statement from the 2014 International Microdialysis Forum.

Microdialysis enables the chemistry of the extracellular interstitial space to be monitored. Use of this technique in patients with acute brain injury has increased our understanding of the pathophysiology of several acute neurological disorders. In 2004, a consensus document on the clinical application of cerebral microdialysis was published. Since then, there have been significant advances in the clinical use of microdialysis in neurocritical care. The objective of this review is to report on the International Microdialysis Forum held in Cambridge, UK, in April 2014 and to produce a revised and updated consensus statement about its clinical use including technique, data interpretation, relationship with outcome, role in guiding therapy in neurocritical care and research applications.We gratefully acknowledge financial support for participants as follows: P.J.H. - National Institute for Health Research (NIHR) Professorship and the NIHR Biomedical Research Centre, Cambridge; I.J. – Medical Research Council (G1002277 ID 98489); A. H. - Medical Research Council, Royal College of Surgeons of England; K.L.H.C. - NIHR Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); M.G.B. - Wellcome Trust Dept Health Healthcare Innovation Challenge Fund (HICF-0510-080); L. H. - The Swedish Research Council, VINNOVA and Uppsala Berzelii Technology Centre for Neurodiagnostics; S. M. - Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico; D.K.M. - NIHR Senior Investigator Award to D.K.M., NIHR Cambridge Biomedical Research Centre (Neuroscience Theme), FP7 Program of the European Union; M. O. - Swiss National Science Foundation and the Novartis Foundation for Biomedical Research; J.S. - Fondo de Investigación Sanitaria (Instituto de Salud Carlos III) (PI11/00700) co-financed by the European Regional Development; M.S. – NIHR University College London Hospitals Biomedical Research Centre; N. S. - Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico.This is the final version of the article. It first appeared from Springer via http://dx.doi.org/10.1007/s00134-015-3930-

A global experiment on motivating social distancing during the COVID-19 pandemic

Finding communication strategies that effectively motivate social distancing continues to be a global public health priority during the COVID-19 pandemic. This cross-country, preregistered experiment (n = 25,718 from 89 countries) tested hypotheses concerning generalizable positive and negative outcomes of social distancing messages that promoted personal agency and reflective choices (i.e., an autonomy-supportive message) or were restrictive and shaming (i.e., a controlling message) compared with no message at all. Results partially supported experimental hypotheses in that the controlling message increased controlled motivation (a poorly internalized form of motivation relying on shame, guilt, and fear of social consequences) relative to no message. On the other hand, the autonomy-supportive message lowered feelings of defiance compared with the controlling message, but the controlling message did not differ from receiving no message at all. Unexpectedly, messages did not influence autonomous motivation (a highly internalized form of motivation relying on one’s core values) or behavioral intentions. Results supported hypothesized associations between people’s existing autonomous and controlled motivations and self-reported behavioral intentions to engage in social distancing. Controlled motivation was associated with more defiance and less long-term behavioral intention to engage in social distancing, whereas autonomous motivation was associated with less defiance and more short- and long-term intentions to social distance. Overall, this work highlights the potential harm of using shaming and pressuring language in public health communication, with implications for the current and future global health challenges

Consensus statement from the 2014 International Microdialysis Forum

This is the final version of the article. It first appeared from Springer via http://dx.doi.org/10.1007/s00134-015-3930-yMicrodialysis enables the chemistry of the extracellular interstitial space to be measured. Use of this technique in patients with acute brain injury has increased our understanding of the pathophysiology of several acute neurological disorders. In 2004 a consensus document on the clinical application of cerebral microdialysis was published. Since then there have been significant advances in the clinical use of microdialysis in neurocritical care. The objective of this review is to report on the International Microdialysis Forum held in Cambridge, UK, in April 2014 and to produce a revised and updated consensus statement about its clinical use including technique, data interpretation, relationship with outcome, role in guiding therapy in neurocritical care and research applications.We gratefully acknowledge financial support for participants as follows: P.J.H. - National Institute for Health Research (NIHR) Professorship and the NIHR Biomedical Research Centre, Cambridge; I.J. ? Medical Research Council (G1002277 ID 98489); A. H. - Medical Research Council, Royal College of Surgeons of England; K.L.H.C. - NIHR Biomedical Research Centre, Cambridge (Neuroscience Theme; Brain Injury and Repair Theme); M.G.B. - Wellcome Trust Dept Health Healthcare Innovation Challenge Fund (HICF-0510-080); L. H. - The Swedish Research Council, VINNOVA and Uppsala Berzelii Technology Centre for Neurodiagnostics; S. M. - Fondazione IRCCS C? Granda Ospedale Maggiore Policlinico; D.K.M. - NIHR Senior Investigator Award to D.K.M., NIHR Cambridge Biomedical Research Centre (Neuroscience Theme), FP7 Program of the European Union; M. O. - Swiss National Science Foundation and the Novartis Foundation for Biomedical Research; J.S. - Fondo de Investigaci?n Sanitaria (Instituto de Salud Carlos III) (PI11/00700) co-financed by the European Regional Development; M.S. ? NIHR University College London Hospitals Biomedical Research Centre; N. S. - Fondazione IRCCS C? Granda Ospedale Maggiore Policlinico

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Exploration of the Suitability of Bicyclic Guanidinates as Ligands in Catalytic Chemistry Mediated by Titanium

The synthesis, structure, and reactivity of titanium complexes supported by the bicyclic guanidinate ligand derived from 1,3,4,6,7,8-hexahydro-2H-pyrimido[1,2-a]pyrimidine (hppH) are described. In situ reaction between a THF solution of the lithium salt, (hppLi)n, and titanium chloride starting materials afforded the series of compounds Ti(hpp)nCl4-n(THF)x [n = 1, x = 1 (1); n = 2, x = 0 (3); n = 3, x = 0 (4)]. The dimeric, base-free complex [Ti(hpp)Cl2(-Cl)]2 (2) was synthesized from the reaction of the silylated ligand precursor, hppSiMe3, with TiCl4 in CH2Cl2. Preliminary olefin polymerization studies of 1-3 using MAO as activator indicated low activities. The reaction between 3 and 2 equiv of AlMe3 resulted in formation of a novel trimetallic Ti(III) species, Ti{AlMe2(hpp)2}Cl(-Cl)AlMe3 (5), highlighting the noninnocent behavior of the ligands. The bis(benzyl) complex Ti(hpp)2(CH2Ph)2 (6) was synthesized from the alkane elimination reaction between the neutral ligand precursor, hppH, and Ti(CH2Ph)4. Attempted generation of the corresponding mono-benzyl cation through reaction with the neutral borane B(C6F5)3 again afforded reduced species. The synthesis of titanium tert-butylimido compounds [Ti(-NtBu)(hpp)Cl]2 (7) and [Ti(NtBu)(hpp)(-hpp)]2 (8) from the salt metathesis reaction of 1 and 2 equiv of (hppLi)n, respectively, with Ti(NtBu)Cl2(py)3 is reported. The molecular structures of compounds 2 and 3 and 5-8 are reported, and the distribution of -electron density throughout the guanidinate ligands is discussed in detail